Grace Therapeutics, Inc. (GRCE)Healthcare | Biotechnology | Princeton, United States | NasdaqCM
4.58 USD
-0.01
(-0.218%) ⇩
(April 21, 2026, 12:30 p.m.
EDT)
Short-term: ★★★☆☆ | Long-term: ★★☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 19, 2026, 12:41 a.m. EDT
Grace Therapeutics is a high-risk speculative vehicle currently trading at the lower bound of its 52-week range despite positive FDA news, driven by its status as a non-dividend paying biotech with negative earnings and no analyst coverage. The recent price volatility suggests technical weakness, but the robust call volume at immediate strikes hints that smart money is positioning for the next catalyst (trial results or capex news) to drive a rebound to at least $5. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.067467 |
| AutoETS | 0.096505 |
| AutoARIMA | 0.097376 |
| MSTL | 0.098767 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 47% |
| H-stat | 5.20 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.848 |
| Excess Kurtosis | 0.27 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 70,871,040 |
| Forward P/E | -7.13 |
| Beta | 0.69 |
| Previous Name | Acasti Pharma Inc. |
| Website | https://www.gracetx.com |
As of April 19, 2026, 12:41 a.m. EDT: Short-term call option volume (April 17) suggests a bullish sentiment with significant vertical positioning at the $5.00 strike (ATM anchor), implying a belief in a near-term move toward or above the current price. However, put volume is notably low for the immediate term. Medium-term (May) flow shows a slight preference for puts over calls regarding SPX IV or specific strikes, suggesting some hedging or minor bearish views if earnings disappoint. There is no signs of massive speculative gamma exposure or deep out-of-the-money momentum bets in the near term.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.0043669 |
| Address1 | 103 Carnegie Center |
| Address2 | Suite 300 |
| All Time High | 2,016.0 |
| All Time Low | 1.72 |
| Ask | 4.73 |
| Ask Size | 1 |
| Average Daily Volume10 Day | 1,255,200 |
| Average Daily Volume3 Month | 483,886 |
| Average Volume | 483,886 |
| Average Volume10Days | 1,255,200 |
| Beta | 0.686 |
| Bid | 4.43 |
| Bid Size | 1 |
| Book Value | 4.194 |
| City | Princeton |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 4.58 |
| Current Ratio | 14.962 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 4.8 |
| Day Low | 4.49 |
| Display Name | Grace Therapeutics |
| Earnings Timestamp End | 1,750,419,000 |
| Earnings Timestamp Start | 1,750,419,000 |
| Ebitda | -11,241,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -4.657 |
| Enterprise Value | 52,353,780 |
| Eps Current Year | -1.155 |
| Eps Forward | -0.64271593 |
| Eps Trailing Twelve Months | -0.31 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 4.1186 |
| Fifty Day Average Change | 0.46140003 |
| Fifty Day Average Change Percent | 0.11202837 |
| Fifty Two Week Change Percent | 100.43669 |
| Fifty Two Week High | 5.18 |
| Fifty Two Week High Change | -0.5999999 |
| Fifty Two Week High Change Percent | -0.1158301 |
| Fifty Two Week Low | 2.15 |
| Fifty Two Week Low Change | 2.4299998 |
| Fifty Two Week Low Change Percent | 1.1302325 |
| Fifty Two Week Range | 2.15 - 5.18 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,328,625,000,000 |
| Float Shares | 9,774,787 |
| Forward Eps | -0.64271593 |
| Forward P E | -7.1260095 |
| Free Cashflow | -6,619,000 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 6 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.27061 |
| Held Percent Institutions | 0.28087 |
| Implied Shares Outstanding | 15,474,027 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,743,379,200 |
| Last Split Date | 1,688,947,200 |
| Last Split Factor | 1:6 |
| Long Business Summary | Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to improve neurological symptoms of Ataxia-Telangiectasia (A-T) and GTX-101, a topical bioadhesive film-forming polymer for the treatment of pain associated with postherpetic neuralgia (PHN). The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. Grace Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey. |
| Long Name | Grace Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 70,871,040 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_47663822 |
| Most Recent Quarter | 1,767,139,200 |
| Name Change Date | 2,026-04-20 |
| Net Income To Common | -5,979,000 |
| Next Fiscal Year End | 1,774,915,200 |
| Non Diluted Market Cap | 71,025,779 |
| Number Of Analyst Opinions | 2 |
| Open | 4.78 |
| Operating Cashflow | -10,128,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 609 322 1602 |
| Prev Name | Acasti Pharma Inc. |
| Previous Close | 4.59 |
| Price Eps Current Year | -3.965368 |
| Price Hint | 4 |
| Price To Book | 1.0920362 |
| Profit Margins | 0.0 |
| Quick Ratio | 14.558 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.010000229 |
| Regular Market Change Percent | -0.21786991 |
| Regular Market Day High | 4.8 |
| Regular Market Day Low | 4.49 |
| Regular Market Day Range | 4.49 - 4.8 |
| Regular Market Open | 4.78 |
| Regular Market Previous Close | 4.59 |
| Regular Market Price | 4.58 |
| Regular Market Time | 1,776,789,033 |
| Regular Market Volume | 368,330 |
| Return On Assets | -0.108389996 |
| Return On Equity | -0.102180004 |
| Sand P52 Week Change | 0.34445214 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 15,474,026 |
| Shares Percent Shares Out | 0.106800005 |
| Shares Short | 1,652,768 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 390,568 |
| Short Name | Grace Therapeutics, Inc. |
| Short Percent Of Float | 0.1257 |
| Short Ratio | 3.31 |
| Source Interval | 15 |
| State | NJ |
| Symbol | GRCE |
| Target High Price | 12.033789 |
| Target Low Price | 10.985429 |
| Target Mean Price | 11.509608 |
| Target Median Price | 11.509608 |
| Total Cash | 18,672,000 |
| Total Cash Per Share | 1.207 |
| Total Debt | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.31 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 3.4587 |
| Two Hundred Day Average Change | 1.1213 |
| Two Hundred Day Average Change Percent | 0.32419696 |
| Type Disp | Equity |
| Volume | 368,330 |
| Website | https://www.gracetx.com |
| Zip | 8,540 |